News for Fulgent Genetics, Inc. (FLGT)

NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices (

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Operator: Greetings, and welcome to the Fulgent Genetics, Inc. Q4 2024 Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsMelanie Solomon - IRMing Hsieh -...

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 133.33% and 1.90%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics, Inc. (NASDAQ: FLGT) (”œFulgent,” or the ”œCompany”), a technology-based company with a well-established laboratory services business an

Quarterly Revenue: $76.2 million, slightly above the estimated $76.09 million.Quarterly EPS: GAAP loss of ($0.19) per share, outperforming the estimated loss o

Fulgent Genetics (FLGT) reports Q4 Non-GAAP EPS of $0.04, beating estimates by $0.16, and revenue of $76M (+7.8% Y/Y).

On December 31, 2024, Barclays PLC made a significant move by acquiring 1,483,204 shares of Fulgent Genetics Inc at a price of $18.47 per share. This transactio

Fulgent Genetics, Inc. (NASDAQ: FLGT) (”œFulgent” or the ”œCompany”), a technology-based company with a well-established laboratory services business and

Shares of Fulgent Genetics Inc (FLGT) fell 4.91% in mid-day trading on Jan 14. The stock reached an intraday low of $16.97, before recovering slightly to $17.

On December 31, 2024, Millennium Management LLC executed a significant stock transaction involving Fulgent Genetics Inc. The firm added 259,997 shares of Fulgen

Fulgent Genetics is a biotech company with a profitable COVID-19 diagnostics segment that will be negligible going forward. Read why I rate FLGT stock a Buy.

Explore the current issues and future potential of Fulgent Genetics, Inc. amid the COVID-19 pandemic and beyond. Click for my FLGT stock update.

The mean of analysts' price targets for Fulgent Genetics (FLGT) points to a 31.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Shares of Fulgent Genetics Inc (FLGT) surged 3.66% in mid-day trading on Dec 2. The stock reached an intraday high of $19.13, before settling at $18.97, up

Fulgent Genetics (FLGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Shares of Fulgent Genetics Inc (FLGT) surged 1.76% in mid-day trading on Nov 20. The stock reached an intraday high of $17.53, before settling at $17.30, up

Fulgent Genetics stock hits 52-week low at $18.76